Aim: This multicenter, observational study aimed to investigate the survival benefit of eribulin as well as that of taxane-based regimens in Japanese patients with metastatic breast cancer (MBC) in a real-world setting. 
INTRODUCTION
The current therapies for metastatic breast cancer (MBC) generally focus on symptomatic control and prolonging survival; however, improvement of long-term survival remains a challenge. Recently, the survival benefit provided by eribulin, a first-in-class halichondrin Bbased microtubule dynamics inhibitor, has been receiving attention. [1] [2] [3] [4] This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. In a phase III randomized controlled trial (EMBRACE), 5 which included patients with heavily pretreated MBC with a median of four previous chemotherapy regimens, eribulin was compared with treatment of physician's choice. The overall survival (OS) of patients who received eribulin was significantly improved compared with those who received treatment of physician's choice. In another phase III trial (study 301), 6 eribulin showed a favorable improvement in OS compared with Asia-Pac J Clin Oncol. 2018;14:e231-e237.
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capecitabine in patients with pretreated MBC with a median of two previous chemotherapy regimens; however, this improvement did not meet the predefined criteria for statistical significance. In addition, a pooled analysis of both the aforementioned phase III trials 7 showed that OS of patients who received eribulin was significantly improved compared with that of those who received a different treatment.
Moreover, most of the nonhematological adverse events in eribulintreated patients were found to be mild; eribulin had minimal toxicity that might contribute to its observed survival benefit in patients with MBC.
In most countries and regions outside of Japan, eribulin has been approved for the treatment of MBC that was previously treated with at least two chemotherapeutic agents, including anthracycline-based and taxane-based regimens, or the treatment of MBC that was previously treated with at least one chemotherapy regimen. In contrast, in Japan, eribulin has been approved for the treatment of patients with inopera- However, taxane-based regimens are preferred for MBC treatment. The increased use of taxanes in early-stage breast cancer leads to higher rates of resistance to these drugs by the time of disease recurrence. 10 We conducted a multicenter, observational study in a real-world clinical setting to investigate the survival benefit of eribulin, as well as that of patients prescribed taxane-based regimens (with or without bevacizumab), which remain the standard chemotherapy options for MBC. 11-13
METHODS

Patients and study design
This was a nonrandomized, observational study of Japanese women with MBC who were planned to receive eribulin or taxane with or without bevacizumab in six institutions in Japan between July 19, 2011, 
Assessments
The primary efficacy endpoint was OS, which was calculated as the 
Statistical analyses
The end of the observation period was September 30, 2015. All efficacy and safety endpoints were assessed. The OS and PFS curves were estimated using the Kaplan-Meier method. Hazard ratios (HRs) and 95% confidence intervals (CIs) for OS, PFS and PPS were estimated using the Cox proportional hazards model. ORRs and disease control rates were estimated using a logistic regression model. Because this was an observational study with possible risk of bias associated with patient demographic characteristics, the odds ratios for ORR and disease control rate were adjusted for history of treatment with anthracycline/taxane, age, ECOG PS, subtype, presence of metastasis and treatment line using logistic regression. 
e233
TA B L E 1 Baseline demographics and clinical characteristics of patients
RESULTS
Patients
A total of 221 patients were included in this study. 
Treatment
At the end of the observation period (median 15.4 months), 97 patients (96.0%) in the eribulin monotherapy group, 73 patients (100%) in the taxane monotherapy group and 41 patients (97.6%) in the taxane plus bevacizumab group had discontinued treatment. The proportion of patients who discontinued because of an increase in the size of the existing tumor was 78.4% in the eribulin monotherapy group, 35.6%
in the taxane monotherapy group and 82.9% in the taxane plus bevacizumab group (Table 2) . Other reasons for discontinuation included the appearance of new distant metastases (11.3%, 41.1% and 9.8%, respectively), adverse events (1.0%, 21.9% and 4.9%, respectively), achievement of CR (7.2%, 0.0% and 0.0%, respectively) and others (2.1%, 1.4% and 2.4%, respectively). Four patients in the eribulin monotherapy group and one in the taxane plus bevacizumab group had continued their treatment regimen through the end of the observation period.
Efficacy
The median OS was 22. 
TA B L E 2 Reasons for discontinuation
Eribulin monotherapy (n = 97) Taxane monotherapy (n = 73) BEV+PTX (n = 41) F I G U R E 1 Unadjusted overall survival (A) and progression-free survival (B) among women with metastatic breast cancer treated with eribulin monotherapy, taxane monotherapy or taxane (paclitaxel) plus bevacizumab monotherapy group and12.9 (95% CI, 9.0-22.5) months in the taxane plus bevacizumab group ( Figure 1A and Table 3 Figure 1B and Table 3 ). The median number of metastases sites at baseline in the eribulin monotherapy, taxane monotherapy and taxane plus bevacizumab groups was two.
For each efficacy endpoint, the HR was adjusted for treatment history, age, ECOG PS, cancer subtype and treatment line ( Table 3 ). 
Safety analyses
Observed adverse events are summarized in 41.1% in the taxane monotherapy group and 16.7% in the taxane plus bevacizumab group. However, the incidence of grade 4 neutropenia was 1.0%, 8.2% and 7.1% in each group, respectively. The incidence of grade 3 neurotoxicity was 5.9%, 28.8% and 31.0% in each group, respectively. The incidences of fatigue and arthralgia were 17.8% and 14.9%, respectively, in the eribulin monotherapy group; 21.9% and 46.6%, respectively, in the taxane monotherapy group; and 28.6% and 30.9%, respectively, in the taxane plus bevacizumab group. Febrile neutropenia was observed in four patients in the taxane monotherapy group; no febrile neutropenia was seen in either the eribulin group or the taxane plus bevacizumab group. A total of 138 deaths occurred during the study, with 50 deaths in the eribulin group and 88 deaths in the taxane group.
The reasons for discontinuation are described in Table 2 . One patient (1.0%), 16 patients (21.9%) and 2 patients (4.9%) discontinued therapy because of adverse events in the eribulin monotherapy, taxane monotherapy and taxane plus bevacizumab groups, respectively. The adverse event leading to discontinuation of eribulin was alopecia (one patient; 1.0%). The most common adverse events leading to discontinuation of taxane monotherapy were febrile neutropenia (four patients; 5.5%), peripheral neuropathy (four patients; 5.5%) and peripheral neuropathy/myalgia (two patients; 2.7%). In the taxane plus bevacizumab group, adverse events leading to discontinuation were schizophrenia (one patient; 2.4%) and peripheral neuropathy/myalgia (one patient; 2.4%).
DISCUSSION
This multicenter observational study investigated the survival benefit of eribulin-based and taxane-based regimens in Japanese patients with MBC. Because of the possible risk of bias associated with patient demographic characteristics, efficacy findings were adjusted for history of treatment. The median OS of eribulin was 22.3 months. These study results suggest that eribulin might have a survival benefit without increasing the risk of toxicity in patients with MBC.
The key goal in the treatment of MBC is to prolong survival, with an emphasis on restricting treatment-related toxicity as much as possible. 14 The introduction of novel chemotherapeutic agents, the growing number of potentially active drugs and combinations of these 4 In a phase III study of chemotherapy with or without bevacizumab, 15 no difference was observed in OS.
In addition, in this study, although the sample size was smaller, a similar trend was suggested.
In previous studies of eribulin, a median PFS of 3.9 months was reported in MBC patients who had received at least one prior chemotherapy, 2 whereas a median PFS of 8. The reason for the longer OS with eribulin remains unclear, but eribulin was recently shown to have clinical effectiveness in taxanerefractory MBC patients. 1 Most of the patients receiving eribulin in this study were pretreated with a taxane-based regimen, and some of these patients may have been taxane refractory. In addition, longer administration of eribulin might be beneficial to maximize the antitumor activities and might contribute to survival benefit. The median exposure to the study drug in patients who received eribulin (7.7 months) was longer than that in patients who received taxane-based regimens (3.8 months; data not shown). Furthermore, the longer PFS and PPS with eribulin may contribute to prolonging the OS. Both the median PFS and median PPS tended to be longer in patients who received eribulin than in those who received a taxane-based regimen.
The most frequent number of sequential lines of treatment in the eribulin group was greater than that for those receiving taxane-based regimens, which was a potential source of bias, and might have also contributed to the long PPS and OS.
The safety profile of eribulin was acceptable. The ECOG PS at baseline was similar among all the groups. Febrile neutropenia and neurotoxicity were the main reason for discontinuation of therapy in patients who received taxane-based regimens; five patients discontinued because of febrile neutropenia and 11 patients discontinued because of neurotoxicity. Approximately 80% of patients in each treatment group had received prior taxane therapy, and drug accumulation may have contributed to the neurotoxicity seen during the observation period. Moreover, the majority of those patients who discontinued therapy because of neurotoxicity were unable to receive additional sequential therapies (data not shown). In contrast, the majority of patients who received eribulin shifted to sequential therapies after discontinuation of eribulin. The adverse events seen with eribulin were manageable, and this might have contributed to the long duration of therapy as well as the long survival outcomes.
The study also found that the incidence of distant metastases at the time of PD was 11.3% in patients receiving eribulin and 41.1% in those receiving taxane (Table 2 ). Prognosis is worse in patients who develop new metastases than in patients with an increase in primary tumor size; this was confirmed in recent studies of eribulin. 17, 18 Because hypoxic conditions favor metastasis, it is possible that eribulin, which improves blood flow and decreases local hypoxia, may contribute to the inhibition of new metastases. 19, 20 This effect of eribulin may have led to the long PPS and, in turn, the long OS in this observational study.
Although there are some existing data from observational studies of eribulin, [21] [22] [23] [24] including patients managed in clinical practice, 25 this study is the first to investigate eribulin-based and taxane-based regimens in a real-world treatment setting. However, this study has some limitations, such as those inherent to the observational study design, and subjective and selection biases may have affected the results.
However, the data were obtained in a real-world clinical setting, providing important information about the long-term benefits of eribulin in MBC patients, despite the observational nature of the study. In addition, the sample size is relatively small, and doses were modified at physicians' discretion. Considering these limitations, interpreting and generalizing the findings should be done with caution; however, the survival benefit remained after adjustment for a variety of factors, In summary, the present study results suggest that eribulin conferred a survival benefit in Japanese patients with MBC as shown by the long PFS and PPS. Taxanes, which are also microtubule inhibitors, showed similar trends. Notably, few patients discontinued eribulin because of adverse events and the types of adverse events in eribulintreated patients were manageable. Additional investigations that compare eribulin and other therapeutic options for treatment of MBC in Japanese patients are warranted.
